Clinical trial
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell…
NCT00201877 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00201877 |
|---|---|
| Title | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Velcade, Rituximab |
| Enrollment | 25 |
| Start date | Dec 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Mar 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: